title: Zoledronic Acid may reduce intraoperative bleeding in spinal tumors: a prospective cohort study.
abstract: Between June 2010 and June 2011, 176 patients were divided into 2 groups: a group with spinal metastasis of solid tumors (n = 157) and a group with multiple myeloma (n = 19). Both groups were further divided into 2 subgroups: a group receiving zoledronic acid before surgery and a control group. The zoledronic acid subgroup of the solid tumors group was group A (n = 81), the control subgroup of the solid tumors group was group B (n = 76), the zoledronic acid subgroup of the multiple myeloma group was group C (n = 10), and the control subgroup of the multiple myeloma group was group D (n = 9). The average intraoperative blood loss during spinal surgery was as follows: 1311 ± 691 mL in group A and 1752 ± 740 mL in group B (P = 0.000) and 1994 ± 810 mL in group C and 3134 ± 795 mL in group D (P = 0.000). Patients receiving zoledronic acid before surgery had significantly less intraoperative bleeding than those who did not receive it. Preoperative use of zoledronic acid can effectively reduce intraoperative bleeding during surgery for the treatment of spinal tumors.
authors: Department of Pharmacy, Chengdu Military General Hospital, Chengdu 610083, China.
authors: Juan
authors: J
authors: Wu
authors: Department of Orthopedics, Chengdu Military General Hospital, Chengdu 610083, China ; Department of Orthopedics, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
authors: Wei
authors: W
authors: Zheng
authors: Department of Science and Training, Chengdu Military General Hospital, Chengdu 610083, China.
authors: Yan
authors: Y
authors: Tan
authors: Department of Training, Second Military Medical University, Shanghai 200433, China.
authors: Xiao-Yuan
authors: XY
authors: Hu
authors: Department of Orthopedics, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
authors: Quan
authors: Q
authors: Huang
authors: Department of Pharmacy, Chengdu Military General Hospital, Chengdu 610083, China.
authors: Kai-Hua
authors: KH
authors: Fan
authors: Department of Pharmacy, Chengdu Military General Hospital, Chengdu 610083, China.
authors: Jie
authors: J
authors: Ma
authors: Department of Pharmacy, Chengdu Military General Hospital, Chengdu 610083, China.
authors: Wen-Jing
authors: WJ
authors: Xiao
authors: Department of Pharmacy, Chengdu Military General Hospital, Chengdu 610083, China.
authors: Jian-Dong
authors: JD
authors: Ren
authors: Department of Pharmacy, Chengdu Military General Hospital, Chengdu 610083, China.
authors: Jun
authors: J
authors: Hou
authors: Department of Orthopedics, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
authors: Jian-Ru
authors: JR
authors: Xiao
mesh_terms: D000328:Adult; D000368:Aged; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D004164:Diphosphonates / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000473:pathology / Q000601:surgery*; D009362:Neoplasm Metastasis; D013125:Spinal Neoplasms / Q000473:pathology / Q000556:secondary / Q000601:surgery*; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid